Amneal expands broad injectables portfolio to over 40 products with the addition of six new therapies

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the company's total number of commercial injectable products available for the u.s. institutional market to over 40. the growth of amneal's broad injectables portfolio will help address shortages of critical products where there may be l.
AMRX Ratings Summary
AMRX Quant Ranking